Advertisement

Allegro Diagnostics Inc., a Maynard developer of medical tests for cancer, has closed a $5.4 million Series A financing round, backed by Kodiak Venture Partners and Catalyst Health Ventures. The funding will be used to move the company’s BronchoGen genomic test, used to detect potential lung cancer signs, into commercialization next year.

The company’s testing platform is made to notice molecular response in a respiratory tract and note any sign of malignant airway cells in the lungs.

SOURCE

Advertisement
Advertisement